Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial

Clinical Oncology : a Journal of the Royal College of Radiologists
P HeudelG Freyer

Abstract

To determine the feasibility of radiotherapy-associated capecitabine, irinotecan and oxaliplatin administration at five dose levels for the treatment of locally advanced rectal cancer, with or without metastasis. This was a bicentric phase I trial, including patients with locally advanced rectal cancer, with or without metastasis. Chemotherapy comprised capecitabine (1100, 1300 or 1500 mg/m2/day, every day), irinotecan (30, 40 or 50mg/m2, once per week for 6 weeks) with the addition of oxaliplatin (40 mg/m2 at level 4 or 50 mg/m2 at level 5, once per week for 6 weeks). Radiotherapy at 46 Gy plus a boost of 4 Gy was administered concomitantly. Twelve patients received four levels of dose. As a supplement to radiotherapy, the combination of capecitabine and irinotecan at the respective doses of 1500 mg/m2/day and 50 mg/m2/week was feasible and well tolerated. The addition of oxaliplatin to this combination provoked toxicity (grade 3/4 vomiting, diarrhoea) for two-thirds of the patients. A treatment associating radiotherapy (46 Gy+4 Gy) with concomitant chemotherapy comprising capecitabine (1500 mg/m2/day, every day) and irinotecan (50 mg/m2/week, for 5 weeks) was feasible and well tolerated. The addition of oxaliplatin to these d...Continue Reading

References

Sep 19, 1990·JAMA : the Journal of the American Medical Association
Nov 1, 1987·International Journal of Radiation Oncology, Biology, Physics·M J Weinberg, A M Rauth
Apr 3, 1997·The New England Journal of Medicine·UNKNOWN Swedish Rectal Cancer TrialN Wilking
Aug 17, 2000·JAMA : the Journal of the American Medical Association·C CammàM Cottone
Sep 24, 2002·International Journal of Radiation Oncology, Biology, Physics·Jun-Sang KimWan-Hee Yoon
Sep 28, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jürgen DunstStefan Frings
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre GérardGilles Freyer
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claus RödelRolf Sauer
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Feb 3, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ralf-Dieter HofheinzFrank Willeke
Oct 13, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-P MachielsC Sempoux
Nov 15, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R Glynne-JonesA C McDonald
Sep 15, 2006·The New England Journal of Medicine·Jean-François BossetUNKNOWN EORTC Radiotherapy Group Trial 22921
Jan 9, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-P MachielsK Haustermans
Apr 28, 2007·Nature Clinical Practice. Oncology·Christopher G WillettRakesh K Jain

❮ Previous
Next ❯

Citations

Aug 3, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Ramon SalazarEnrique Aranda
Jul 22, 2010·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·S Gollins
May 16, 2017·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·J MooreP Hewett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.